GLIPR1 and type 1 diabetes mellitus: While both T cell and autoantibody responses against EpCAM have been reported in cancer patients, there have been no previous reports of immune responses against either EpCAM or GLIPR1 in subjects with type I diabetes [23]–[25], highlighting the ability of synthetic minigene screening to identify truly novel antigens.